Owlet, Inc. (NYSE: OWLT) announced on 16 October 2025 that the Central Drugs Standard Control Organization (CDSCO) has approved its Dream Sock® for distribution in India. The approval marks the first time the company’s medical‑grade infant monitor has cleared India’s stringent regulatory framework, enabling the company to move forward with a planned launch of its integrated Dream Sock, Dream Sight, and Dream Duo product line in early 2026.
India is a strategic growth market, with an estimated 23 million babies born in 2025—the highest birth cohort worldwide. The CDSCO clearance positions Owlet to capture a share of this large, underserved market, where smartphone penetration exceeds 80 % in urban centers and demand for connected health solutions is accelerating. The company plans to make its products available through retail and specialty baby stores across the country, leveraging its existing global distribution network and over 2 million families already using Owlet’s platform.
Jonathan Harris, Owlet’s President and CEO, said the approval “validates the clinical rigor of our technology and confirms that Owlet is one of the few infant health companies that can meet India’s demanding medical device requirements.” He added that the company is “excited to bring its real‑time infant health insights to families in India, where early detection tools can have a profound impact on infant health outcomes.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.